Accelerator Labs for Biotech Startups | JLABS
Edit

Accelerator Labs for Biotech Startups | JLABS

http://jlabs.jnjinnovation.com/partners/chimera-bioengineering
Last activity: 08.05.2026
Probably Closed
Categories: DrugInformation
Our mission at ImmuneTarget is to develop novel Rel/NF-kB inhibitor drugs for cancer and autoimmune diseases.
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com
Mentions
42

Investors 2

Mentions in press and media 42

DateTitleDescription
13.05.2026Modicus Prime Secures $8 Million to Revolutionize Pharma AI ComplianceModicus Prime secured $8 million total funding, with a fresh $4.5 million infusion. This investment fuels its mission to provide robust AI compliance infrastructure for the pharmaceutical industry. The company's Trustworthy AI Compliance So...
08.05.2026Modicus Prime: $8 Million Raised To Expand AI Compliance Infrastructure For PharmaModicus Prime announced it raised a total of $8 million in funding following an additional $4.5 million investment led by Frist Cressey Ventures, with participation from Silverton Partners and Oncology Ventures. The company said the financi...
01.08.2025Houston's 13 best midsize companies and more innovation news to knowEditor's note: The top innovation news from the second half of the month includes new leaders at innovative Houston organizations and a ranking of the best midsize businesses from Time. Here are the five most-read InnovationMap stories from...
31.07.2025Houston tech jobs to grow in 2025 as Texas leads U.S. in new tech employmentTech employment in the Houston metro area is expected to climb by more than two percent this year, according to a new projection. CompTIA’s State of the Tech Workforce 2025 report forecasts the Houston area will employ 158,176 tech professi...
14.06.2024Singapore Science Park: An industry campus evolves into a hotspot for work, play and livingListen to this article Singapore Science Park: An industry campus evolves into a hotspot for work, play and living 1 min New: You can now listen to articles. This audio is generated by an AI tool. How does your workday typically begin? Imag...
16.06.2022BIO: 'Diversity candidates' and knowledge 'shortfalls': Women in biotech say 'I'm here to do my job' despite toxic tropesThe script at BIO this year could not have been more clear: Progress on diversity is being made, but more work needs to be done. Yet still, an undercurrent of biotech’s all-boys brand-of-old tugged at the heels of efforts to bolster those l...
12.05.2022ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal SprayENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected...
11.05.2022ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal SpraySYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk popu...
23.02.2022BIORCHESTRA Announces 45 Million USD Series C FundraisingSEOUL, South Korea, Feb. 23, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms. Today, BIORCHESTRA...
05.10.2021Акселераторы, о которых должны знать MedTech-стартапыАкселераторы, о которых должны знать MedTech-стартапы
Show more

Reviews 0

Sign up to leave a review

Sign up Log In